How effective is natalizumab (Tysabri) in the treatment of relapsing-remitting multiple sclerosis (MS) (RRMS), and what is its dosage regimen?

Updated: Oct 08, 2019
  • Author: Christopher Luzzio, MD; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print

In a placebo-controlled clinical trial, the use of natalizumab reduced the relapse rate (68%) and progression of disability (42%) over a period of 2 years. [96] Natalizumab is given as a 300 mg IV infusion over 1 hour every 4 weeks.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!